A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies

September 20, 2019

Primary Outcome Measures

Incidence of treatment-emergent adverse events (TEAEs) [ Time Frame: Up to 5.5 years ]
Incidence of treatment-emergent serious adverse events (TESAEs) [ Time Frame: Up to 5.5 years ]
Incidence of drug-related TEAEs [ Time Frame: Up to 5.5 years ]
Incidence of drug-related TESAEs [ Time Frame: Up to 5.5 years ]

Secondary Outcome Measures

Overall survival [ Time Frame: Up to 5.5 years ]

Inclusion Criteria

Participants ongoing in an applicable Bayer-sponsored anetumab ravtansine parent study at the time of its planned study closure.
For on-treatment participants: participant is eligible to receive the next dose of study intervention per the parent study protocol.

Exclusion Criteria

For on-treatment participants: a positive serum pregnancy test.
For on-treatment participants: use of one or more of the prohibited medications listed in the respective parent study protocol.
Participants who are receiving standard-of-care agent(s) but not anetumab ravtansine in the parent study, and are able to receive standard-of-care agent outside of the clinical study.

CONTACT INFORMATION

Name*

First Last

Email*

Phone*

Address*

Street Address Address Line 2 City State / Province / Region ZIP / Postal Code Country

Have you received a diagnosis?*

Yes

DIAGNOSIS

Diagnosis?*

Date of Diagnosis*

Comments*

Name

This field is for validation purposes and should be left unchanged.

Quick Facts

Accepts Healthy Volunteers
Ages Available for Study
ClinicalTrials.gov Identifier
Collaborators
Contacts(s)
Location(s)
Estimated Enrollment
Estimated Study Start Date
Estimated Primary Completion Dates
Full Title
Genders Eligible for Study
Investigator(s)
Last Updated
Other Contact